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Background: Kidney stone disease (KSD) is a complex disorder with unknown etiology in majority of the patients.
Genetic and environmental factors may cause the disease. In the present study, we used DNA microarray to
genotype single nucleotide polymorphisms (SNP) and performed candidate gene association analysis to determine
genetic variations associated with the disease.
Methods: A whole genome SNP genotyping by DNA microarray was initially conducted in 101 patients and 105
control subjects. A set of 104 candidate genes reported to be involved in KSD, gathered from public databases and
candidate gene association study databases, were evaluated for their variations associated with KSD.
Results: Altogether 82 SNPs distributed within 22 candidate gene regions showed significant differences in SNP
allele frequencies between the patient and control groups (P < 0.05). Of these, 4 genes including BGLAP, AHSG,
CD44, and HAO1, encoding osteocalcin, fetuin-A, CD44-molecule and glycolate oxidase 1, respectively, were further
assessed for their associations with the disease because they carried high proportion of SNPs with statistical
differences of allele frequencies between the patient and control groups within the gene. The total of 26 SNPs
showed significant differences of allele frequencies between the patient and control groups and haplotypes
associated with disease risk were identified. The SNP rs759330 located 144 bp downstream of BGLAP where it is a
predicted microRNA binding site at 3′UTR of PAQR6 – a gene encoding progestin and adipoQ receptor family
member VI, was genotyped in 216 patients and 216 control subjects and found to have significant differences in its
genotype and allele frequencies (P = 0.0007, OR 2.02 and P = 0.0001, OR 2.02, respectively).
Conclusions: Our results suggest that these candidate genes are associated with KSD and PAQR6 comes into our
view as the most potent candidate since associated SNP rs759330 is located in the miRNA binding site and may
affect mRNA expression level.
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Kidney stone disease (KSD) is a major clinical problem
causing medical care expenses and public health burden
worldwide. The etiology of kidney stone is heteroge-
neous, ranging from monogenic defect to complex inter-
action between genetic and environmental factors [1].
KSD is endemic in the northeastern (NE) population of
Thailand. The most recent investigation from our group
demonstrated that it is indeed prevalent in this popula-
tion and the risk of having the disease is higher among
members of affected families, compared to that of the
normal control population, indicating an involvement of
a genetic factor, although its actual etiology is still un-
identified [2].
The technology to identify genetic polymorphisms, es-
pecially single nucleotide polymorphism (SNP), is avail-
able as a tool for studying genes associated with many
diseases [3,4]. Genetic contribution to kidney stone for-
mation has been well recognized, and a number of stud-
ies have reported genetic variations of several human
genes, including osteopontin (OPN) [5,6], calcitonin re-
ceptor (CTR) [7], vitamin D receptor (VDR) [8], urokin-
ase [9], interleukin (IL-1β and IL-Ra) [10,11], E-cadherin
[12], androgen-oestrogen receptors (AR and ER) [13], vas-
cular endothelial receptor growth factor (VEGF) [14], and
calcium-sensing receptor (CaSR) [15], which associated
with KSD with a predominantly hypercalciuria and cal-
cium oxalate kidney stones. However, these reported
genes had little effect on clarifying the contribution to
KSD and a frequent genetic abnormality causing the dis-
ease has not been elucidated. Two previous genome-
wide association studies (GWAS) examined the whole
genomic DNA with many thousands of SNPs and re-
ported genes that were associated with KSD. Sequence
variations in claudin 14 (CLDN14) gene associated with
KSD in the population from Iceland and the Netherlands
have been reported [16]. Subsequently, the same re-
search group described that uromodulin (UMOD) vari-
ant affected risk of chronic kidney disease by providing
protection against KSD [17].
To investigate genetic variations associated with KSD in
NE Thai population, our group has previously reported the
result of case–control association study in 112 subjects
each of patient and control groups. We genotyped 67 SNPs
distributed within 8 candidate genes, namely TFF1,
S100A8, S100A9, S100A12, AMBP, SPP1, UMOD, and F2,
that encode stone inhibitor proteins, including trefoil factor
1, calgranulin (A, B, and C), bikunin, osteopontin, Tamm-
Horsfall protein, and prothrombin, respectively. We found
that minor allele and homozygous genotype frequencies of
8 from 10 analyzed SNPs distributed within the F2 gene
were significantly higher in the control group than those in
the patient group. In addition, two F2 haplotypes were
found to be dually associated with kidney stone (one withdecreased risk and the other with increased risk) in the fe-
male group, indicating that F2 variations influence the risk
of KSD in the NE Thai female patients [18]. We further ex-
amined and reported the association between a specific F2
variation (T165M) and KSD in our recent work [19].
The genes that have been reported for their associ-
ation with KSD in other populations may serve as candi-
date genes for initial screening in the population of
interest that is affected by this disease. In this study, we
initially carried out a whole genome SNP genotyping by
DNA microarray. The genetic variations associated with
KSD in the NE Thai population were then determined
by candidate gene association study using data of the re-
ported candidate genes involved in KSD. The result
showed that at least four candidate genes were associ-
ated with KSD in the NE Thai population studied.
Methods
Subjects
The study was approved by Siriraj Institutional Review
Board and the Ethics Committees of the Ministry of
Public Health, Thailand. A written informed consent
was obtained from individual subject before conducting
this study. A group of 216 patients with KSD (135 fe-
males and 81 males, aged 22–80 years), recruited from
Khon Kaen Regional Hospital in the northeastern part of
Thailand, were studied. Of these, 64% have family his-
tory. The 216 healthy control subjects (126 females and
90 males), who were age-matched, unrelated, and had
no history of KSD, were recruited from the same geo-
graphical region. More details of the patients and the
healthy control subjects as well as the diagnostic proce-
dures have been described in our previous report [19].
Genomic DNA samples of the patients and control sub-
jects were extracted from peripheral blood samples using
the standard phenol-chloroform method.
Genotyping
The genomic DNA samples from 101 patients and 105 nor-
mal control subjects were genotyped by using the Affyme-
trix Genome-Wide Human SNP Array 6.0 and followi-
ng the manufacturer’s instructions (http://www.affymetrix.
com/support/technical/byproduct.affx?product=genomewi-
desnp_6). The genotyping was conducted by Vanderbilt
Functional Genomics Shared Resource (Vanderbilt Univer-
sity, USA). Briefly, genomic DNA (500 ng) was digested
with Nsp I and Sty I restriction enzymes and ligated to
adaptors. A single generic primer that recognizes the
adaptor sequence was used to amplify adaptor-ligated DNA
fragments. PCR amplification products for each restriction
enzyme digest were combined and purified using polystyr-
ene beads. The amplified products were then fragmented,
labeled, and hybridized to a SNP Array 6.0. Genotyping
Console™ Software was used for genotype calling.
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Candidate genes for KSD were searched and chosen for
the study and statistical analysis from data sources pre-
sented during 1990–2011. Traditional or manual litera-
ture search was carried out using PubMed database
(http://www.ncbi.nlm.nih.gov/pubmed/). Two additional
resources, SNPs3D (http://snps3d.org/) [20] and HuGE
Navigator (http://www.hugenavigator.org/HuGENaviga-
tor/home.do) [21], were also used to assist in screening
candidate genes from published human genetic associ-
ation studies using the keywords related to KSD. Candi-
date genes were selected according to the following
criteria: encoding protein involving in KSD (i.e. ion ex-
change or ion channel protein), stone promoter or in-
hibitor proteins, proteins involving pathways of calcium,
kidney acid–base homeostasis proteins, and metabolic
enzymes.Determination of SNPs in candidate gene regions
SNPs in candidate gene regions (including 1 kb up-
stream and 1 kb downstream of transcript position)
from the genotyping result of 101 case and 105 control
subjects were determined for their association with KSD.
SNPs with call rate of genotyping less than 90% were ex-
cluded. Candidate genes that showed significant differ-
ences of SNP allele frequencies between the patient and
control groups were further assessed for their involve-
ment in the disease by analyses of their individual SNPs
and haplotypes.Sequencing
Specific primers for PCR amplification and sequencing
in the regions of promoter, all exons, and exon-intron
boundaries of BGLAP and AHSG genes were designed
by Primer3 program (http://frodo.wi.mit.edu/primer3/)
(the sequences of PCR primers are available on request).
PCR amplification and sequencing were performed in 6
patients and 6 control subjects. The PCR was performed
using the Immolase™ DNA polymerase (Bioline, USA)
with 0.5 pmol each of forward and reverse primers, 1x
Immolase buffer, 1.5-3 mM MgCl2 and 100 ng of gen-
omic DNA. The cycling conditions were set as follows:
one cycle at 94°C for 10 min, 30 cycles of denaturation
at 94°C for 30 sec, annealing at 64-67°C for 1 min, and
extension at 72°C for 45 sec.
The PCR products were purified for direct sequencing
by using ExoSAP-ITW (Affymetrix, USA). All sequencing
PCR reactions were conducted under BigDye™ Termin-
ator Cycling conditions using 3730XL DNA analyzer
(Applied Biosystems™, USA) by Macrogen Inc (South
Korea). The sequences were evaluated and compared
with the reference nucleotide sequences of BGLAP
(NC_000001.10) and AHSG (NC_000003.11) by multiplesequence alignment using ClustalW2 program (http://
www.ebi.ac.uk/Tools/clustalw2/index.html).
SNP genotyping by a high-resolution melting method
Three SNPs located in BGLAP gene region and the adja-
cent PAQR6 gene (a novel SNP in exon 3, rs759330, and
rs7513351) and two SNPs (rs4917 and rs4918) of AHSG
were genotyped by high-resolution melting (HRM)
method. PCR and HRM analysis for these SNPs were
prepared in 384-well plate and performed on a LightCy-
cler 480 II machine (Roche Diagnotics, Germany). All
PCR reactions were optimized by performing reactions
in 20 μL volumes containing 125 ng genomic DNA in 1x
Immolase buffer, 0.5 μM of each primer, 0.2 mM dNTP,
1.5 mM MgCl2, 0.25 unit of DNA polymerase (Immo-
lase, Bioline, USA), and 1x Resolight dye (Roche Diag-
nostics, Germany). The PCR condition included an
initial denaturation at 95°C for 10 min, followed by
35 cycles of 95°C for 20 sec, 60-68°C for 20 sec, and
72°C for 20 sec. Before the HRM step, the product was
heated to 95°C for 30 sec and then cooled to 40°C. Melt-
ing curves were obtained by increasing the temperature
from 65-97°C with 25 acquisitions of continuous flores-
cence detection. The melting curves were normalized,
temperature-shifted and converted to difference plots by
Gene Scan software. The sequences of PCR primers are
available on request.
In some cases in which the melting curves and differ-
ence plots of amplicons from the samples with homo-
zygous wild-type and variants were unable to be
differentiated, they were further analyzed by spiking the
DNA sample carrying homozygous wild-type into the
tested samples to allow the detection of heteroduplex
DNA molecules generated from the homozygous variant
samples [22,23].
Statistical analysis
According to the SNP genotyping data of microarray,
significant difference SNPs (P < 0.05) between 101 pa-
tients and 105 normal control subjects were examined
by GenABEL package with no adjustment for binary
traits; the test is equivalent to the Armitage test [24].
Statistical tests for Hardy-Weinberg equilibrium (HWE) and
for association between SNP frequencies and disease




P-values were calculated using a chi-square test or Fisher’s
exact test. P < 0.05 was considered statistically significant
in the calculation to compare their differences. The
Haploview software package was used to estimate the
pair-wise linkage disequilibrium (LD) and haplotype block
structure using the confidence intervals algorithm.
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multiplying P-value by the number of observed
haplotypes.
Results
Candidate genes for kidney stone disease
To identify and collect candidate genes involved in KSD,
all published articles or abstracts in the genetic studies
of KSD and its genetic association studies were searched
both from the PubMed database and by using SNPs3D
and HuGE Navigator. Altogether 104 candidate genes
(97 genes on autosome and 7 genes on chromosome X)
were gathered: 48 genes from manual literature search
from PubMed, 64 genes from SNPs3D, and 49 genes
from Phenopedia of HuGE Navigator (Additional file 1:
Table S1).
Potential candidate genes with significant SNPs
A total of 1,559 SNPs located within 104 candidate gene
regions were taken from the genotyping results analyzed
by using Affymetrix Genome-Wide Human SNP ArrayTable 1 Candidate genes and SNPs associated with KSD
Gene Number of SNP in gene regi























aSNP was significantly different between patients and control subjects only in male
bSNP was significantly different between patients and control subjects only in fema
cUncorrected P-value.6.0 of the patient and normal control groups and were
primarily evaluated for their variations associated with
KSD. Several criteria were considered for further selec-
tion, i.e., number of analyzed SNP on microarray, num-
ber of significant SNP, ratio of significant SNP and SNP
on microarray of each gene, gene expression data, and
protein function information. The result demonstrated
that 82 SNPs distributed within 22 candidate gene re-
gions, 20 genes on autosome and 2 genes on chromo-
some X, showed significant differences of SNP allele
frequencies between the patient and control groups (un-
corrected P < 0.05) (Table 1). After Bonferroni’s correc-
tion for 1,559 comparisons, the new statistical
significance cut off is P = 0.000032 and none of SNP can
pass this requirement. Of these, 5 candidate genes, in-
cluding BGLAP, SLC2A9, EGFR, CD44, and HAO1, had
at least one SNP that showed highly significant differ-
ences of allele frequencies between the patient and con-
trol groups at P < 0.005. By taking the number of SNP
with significant P-value within the gene into consider-
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molecule, and glycolate oxidase 1, respectively, were se-
lected to be further assessed for their involvement in
KSD by analyses of individual SNPs and haplotypes be-
cause they carried high proportion of SNPs with statis-
tical differences of allele frequencies between the patient
and control groups within the gene (ClinVar database
accession number: SCV00147950-66). The detail of each
candidate gene is described below.
BGLAP
Only one SNP, rs759330, located 144 bp downstream of
BGLAP gene was identified from the result of DNA
microarray. This SNP was in HWE and showed signifi-
cant differences of allele frequency between the patient
and control groups with P = 0.0009. The analysis also
revealed that genotype frequency significantly differed
(P = 0.0027) with the model of dominant inheritance that
gave the least value of Akaike’s Information Criterion
(AIC). The patient group had significantly higher pro-
portions of the combination of heterozygous genotypes
of major/minor alleles (T/C) and homozygous genotypes
of minor alleles (C/C) than that of the control group, in-
dicating that C allele was susceptible to KSD with odds
ratio (OR) 2.44 (Table 2). However, this association was
not statistically significant after correction for 1,559
comparisons. To confirm this association, we conducted
the genotyping of SNP rs759330 in 101 patients and 105
controls and the additional DNA samples of 115 patients
and 111 controls to make up the total numbers of 216
each of patient and control groups by the HRM method.
The differences of allele and genotype frequencies be-
tween the patient and control groups were statistically
significant at P = 0.0001 and 0.0007 (corrected P =
0.0005 and 0.0035), respectively (Table 2).
To examine whether there were other SNPs linked to
SNP rs759330, the whole BGLAP gene including its pro-
moter region, all 4 exons and introns were amplified (as
a single fragment) and sequenced in 6 patients and 6
normal control subjects. An exoinc non-synonymousTable 2 Genotype and allele frequencies of SNP rs759330 in B
Genotype Genotype frequency (%) OR (95% CI) P-value
(Corrected)Control Patient
SNP array (n = 105) (n = 101)
T/T 75.2 55.5 1.00 0.0027 (4.2093
T/C, C/C 24.8 44.5 2.44 (1.35-4.41)
HRM (n = 216) (n = 216)
T/T 75.0 59.7 1.00 0.0007 (0.0035
T/C, C/C 25.0 40.3 2.02 (1.34-3.05)
OR, odds ratio; CI, confidence interval.
Corrected P-values are adjusted for multiple comparisons (1,559 tests for SNP array
P = 0.00032 and P = 0.01 for the analyses by SNP array and HRM, respectively.
Significant P-values are indicated in bold.SNP rs182775321 was detected. However, the results of
genotyping of this SNP carried out by the HRM method
in 112 of each of patient and control groups showed no
significant differences of genotype and allele frequencies
between the patient and control groups (P = 0.780 and
0.778). In addition, the results of genotyping of
rs7513351 – a SNP positioned 664 bp from rs759330
which is located on PAQR6 gene nearby the BGLAP –
carried out by the HRM method in 112 of each of
patient and control groups showed no significant differ-
ences of genotype and allele frequencies between the pa-
tient and control groups (P = 0.960 and 0. 0.831) (data
not shown).
The Haploview software package was used to estimate
the pair-wise linkage disequilibrium (LD) and haplotype
block structure from the genotyping data of 3 SNPs
(rs182775321, rs759330, and rs7513351) from 101 pa-
tients and 105 control subjects. The result showed that
these 3 SNPs were not in LD block.
AHSG
Three SNPs (rs2248690, rs2070634, and rs2070635) lo-
cated in AHSG gene region were analyzed. All analyzed
SNPs were in HWE. SNP allele frequencies showed sig-
nificant differences between the patient and control
groups for 2 SNPs located in intron 4, rs2070634 and
rs2070635 (P = 0.0329 and 0.0256). Analysis of individual
SNPs in patient and control groups using the web-based
SNPStats program revealed that genotype frequencies of
rs2070634 and rs2070635 significantly differed (Table 3).
The model of inheritance considered by the least value
of AIC was found to be recessive for both SNPs with sig-
nificant differences. The patient group had significantly
higher proportions of homozygous genotypes of minor
alleles than that of the control group for rs2070634 and
rs2070635 (P = 0.023 and 0.017), indicating that homozy-
gous genotypes of minor alleles were susceptible to kid-
ney stone with ORs 2.49 and 2.52, respectively.
One LD block spanning 6 kb containing all 3 SNPs
was defined from the genotyping data of 101 patientsGLAP gene
Allele Allele frequency (%) OR (95% CI) P-value
(Corrected)Control Patient
(n = 105) (n = 101)
) T 87.1 74.3 1.00 0.0009 (1.4031)
C 12.9 25.7 2.35 (1.41-3.92)
(n = 216) (n = 216)
) T 87.0 76.9 1.00 0.0001 (0.0005)
C 13.0 23.1 2.02 (1.41-2.90)
and 5 tests for HRM method). Statistical significance cut off values are
Table 3 Genotype and allele frequencies of SNPs in AHSG gene observed in 105 control subjects and 101 patients
SNP ID Genotype Genotype frequency (%) OR (95% CI) P-value* Allele Allele frequency (%) OR (95% CI) P-value*
Control Patient Control Patient
rs2070634 G/G, G/T 90.5 79.2 1.00 0.023 G 65.7 55.4 1.00 0.0329
T/T 9.5 20.8 2.49 (1.11-5.60) T 34.3 44.6 1.54 (1.03-2.29)
rs2070635 C/C, C/T 89.5 77.2 1.00 0.017 C 65.2 54.5 1.00 0.0256
T/T 10.5 22.8 2.52 (1.60-5.49) T 34.8 45.5 1.57 (1.06-2.33)
OR, odds ratio; CI, confidence interval.
*Uncorrected P-value.
Significant P-values are indicated in bold.
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(Additional file 2: Figure S1, Additional file 3: Table S2).
The most common haplotype, AGC (frequency = 0.600),
was significantly more frequent in the control group
(frequency = 0.652) than in the patient group (fre-
quency = 0.545) with a P-value of 0.0256 (OR 0.64, 95%Table 4 Genotype and allele frequencies of SNPs in CD44 gen
SNP ID Genotype Genotype frequency (%) OR (95% CI) P
Control Patient
rs353623 C/C 69.2 83.2 1.00
C/T, T/T 30.8 16.8 0.46 (0.23-0.89)
rs353618 A/A 69.5 83.2 1.00
A/G, G/G 30.5 16.8 0.46 (0.24-0.90)
rs353612 C/C 86.7 95 1.00
C/T, T/T 13.3 5 0.34 (0.12-0.98)
rs353637 T/T 87.1 96 1.00
T/A 12.9 4 0.29 (0.09-0.91)
rs353630 G/G 86.7 95 1.00
G/A 13.3 5 0.34 (0.12-0.98)
rs353647 G/G 50.5 70.3 1.00
G/C, C/C 49.5 29.7 0.43 (0.24-0.76)
rs3794110 C/C 74 87 1.00
C/T, T/T 26 13 0.43 (0.21-0.88)
rs3794109 A/A 74.3 87.1 1.00
A/G, G/G 25.7 12.9 0.43 (0.21-0.88)
rs112762 C/C 42.9 58.4 1.00
C/T, T/T 57.1 41.6 0.53 (0.31-0.93)
rs10488809 T/T 75.2 87.1 1.00
T/A, A/A 24.8 12.9 0.45 (0.22-0.93)
rs3794105 G/G 86.7 95 1.00
G/A 13.3 5 0.34 (0.12-0.98)
rs7110737 T/T 36.2 43.6 1.00
T/A, A/A 63.8 56.4 0.73 (0.42-1.29)
rs7116432 C/C 43 55.2 1.00
C/T, T/T 57 44.8 0.61 (0.35-1.08)
OR, odds ratio; CI, confidence interval.
*Uncorrected P-value.
Significant P-values are indicated in bold.CI 0.43 - 0.951), indicating its association with decreased
disease risk. In contrast, ATT haplotype was more repre-
sented in the patient group (frequency = 0.285) than in
the control group (frequency = 0.186) with a P-value of
0.0170 (OR 1.743, 95% CI 1.098 -2.769), indicating its as-
sociation with increased disease risk. However, aftere observed in 105 control subjects and 101 patients
-value* Allele Allele frequency (%) OR (95% CI) P-value*
Control Patient
0.018 C 81.2 90.6 1.00 0.0066
T 18.8 9.4 0.45 (0.25-0.81)
0.021 A 81.4 90.6 1.00 0.0075
G 18.6 9.4 0.45 (0.25-0.82)
0.034 C 92.9 97.5 1.00 0.0275
T 7.1 2.5 0.33 (0.12-0.92)
0.022 T 93.6 98 1.00 0.0286
A 6.4 2 0.30 (0.10-0.94)
0.034 G 93.3 97.5 1.00 0.0426
A 6.7 2.5 0.35 (0.13-1.00)
0.0035 G 71.4 83.7 1.00 0.0030
C 28.6 16.3 0.49 (0.30-0.79)
0.019 C 87 93 1.00 0.0446
T 13 7 0.50 (0.26-0.99)
0.019 A 87.1 93.1 1.00 0.0446
G 12.9 6.9 0.50 (0.26-0.99)
0.025 C 65.2 76.7 1.00 0.0103
T 34.8 23.3 0.57 (0.37-0.88)
0.028 T 87.6 93.1 1.00 0.0618
A 12.4 6.9 0.53 (0.27-1.04)
0.034 G 93.3 97.5 1.00 0.0426
A 6.7 2.5 0.35 (0.13-1.00)
0.28 T 58.1 67.8 1.00 0.0411
A 41.9 32.2 0.66 (0.44-0.98)
0.087 C 65 74.5 1.00 0.0413
T 35 25.5 0.64 (0.41-0.98)
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were not statistically significant (P = 0.0768 and 0.0510).
All of the 7 exons, including exon-intron boundary, and
promoter region of AHSG gene were amplified and se-
quenced in 6 patients and 6 control subjects. A total of 3
exonic SNPs were detected, a synonymous SNP (rs4831)
in exon 1 and two non-synonymous SNPs (rs4917 and
rs4918) in exons 6 and 7, respectively. Genotyping of 2
non- synonymous SNPs, rs4917 and rs4918, was carried
out by HRM method in 112 each of patient and control
groups. However, no significant differences of allele and
genotype frequencies between the patient and control
groups of both SNPs were found (P = 0.203 and 0.242)
(data not shown).
CD44
A total of 52 SNPs located in CD44 gene region were ana-
lyzed. Three monomorphic SNPs (rs1467558, rs10488811,
and rs16927100) were observed and were excluded from
further statistical analysis. Allele frequencies of 12 SNPs
showed significant differences (P < 0.05) between the pa-
tient and control groups (Table 4). Analysis of individual
SNPs in the patient and control groups by using the
SNPStats program revealed 11 SNPs with significant dif-
ferences of genotype frequencies. In the dominant model
of inheritance for these SNPs, the control group had
significantly higher proportions of the combination of het-
erozygous genotypes of major/minor alleles and homozy-
gous genotypes of minor alleles than that of the patient
group, indicating that minor alleles were protective to
KSD with ORs between 0.29 and 0.53 (Table 4).
Seven LD blocks containing 8, 3, 2, 2, 6, 3 and 4 SNPs
were defined from the genotyping data of 101 patients
and 105 control subjects with 4, 3, 3, 2, 5, 4 and 3
observed haplotypes for blocks 1–7 (Additional file 4:
Figure S2 and Additional file 5: Table S3). The
GTGTTGGC, AAC, and CCATTC haplotypes of the
blocks 1, 2 and 5 were significantly more frequent in
controls than patients with P = 0.0075, 0.0414, and
0.0082, respectively, indicating its association with de-
creased disease risk. In contrast, the GCACTC and ACC
haplotypes of the blocks 5 and 6 were significantly more
frequent in the patients than the controls with P =
0.0103 and 0.0114, respectively, indicating the associ-
ation with increased disease risk. After Bonferroni’s cor-
rection for multiple testing by multiplying P-value by
the number of observed haplotypes in each block, the
differences remained statistically significant only for the
haplotypes GTGTTGGC, CCATTC and ACC of blocks
1, 5, and 6 (P = 0.03, 0.041, and 0.0456, respectively).
HAO1
All 35 SNPs on microarray located in HAO1 gene region
were analyzed for HWE and genotype and allele frequenciesof the patient and control groups. Initially, 3 SNPs
(rs1983560, rs2423331, and rs7271299) which were
found to have low call rate of genotyping (less than
90%) in either the patient or control groups were dis-
qualified. Two monomorphic SNPs (rs8124232 and
rs16994134) were observed in both groups and were ex-
cluded from further statistical analysis. Allele frequen-
cies of 11 SNPs showed significant differences (P < 0.05)
between the patient and control groups (Table 5). Ana-
lysis of individual SNPs in the patient and control
groups using the SNPStats program revealed significant
differences of genotype frequencies of 10 SNPs. The
model of inheritance considered by the least value of
AIC was found to be dominant for the SNPs with sig-
nificant differences. The patient group had significantly
higher proportions of the alleles than that of the control
group, indicating that associated alleles increase the risk
of KSD (Table 5).
Three LD blocks spanning 17, 20, and 7 kb containing
5, 12, and 2 SNPs were defined from the genotyping data
of 101 patients and 105 control subjects with 4, 5, and 2
observed haplotypes for blocks 1, 2, and 3, respectively
(Additional file 6: Figure S3 and Additional file 7: Table S4).
The GGGAC haplotype of the first block was signifi-
cantly more frequent in the patients than in the controls
with P = 0.0193 (OR 1.615, 95% CI 1.08- 2.414), indicat-
ing its association with increased disease risk. In con-
trast, the CAACGCTCAAAG and AT haplotypes of the
second and the third blocks were significantly more fre-
quent in the controls than in the patients with P =
0.0045 (OR 0.479, 95% CI 0.286-0.801) and 0.0399 (OR
0.598, 95% CI 0.365- 0.979), indicating the association
with decreased disease risk. After Bonferroni’s correction
for multiple testing by multiplying P-value by the number
of observed haplotypes in each block, the differences
remained statistically significant only for the haplotype
of block 2 (P = 0.0225).Discussion
Over the last decade, a number of studies have been
conducted to identify genetic factors contributing to
KSD. Candidate gene approach is an important tool for
this endeavour. In the present candidate gene association
study, initially conducted in 101 NE Thai patients and
105 control subjects, we identified 82 different SNPs in
22 genes that showed suggestive associations with KSD
from the initial analysis of 104 reported candidate genes.
Four genes, including BGLAP, AHSG, CD44, and HAO1,
were selected as candidate genes of KSD in NE Thai
population for further analyses since they carried SNPs
with highly statistical differences (P < 0.005) of allele fre-
quencies between the patient and control groups and
high proportion of significant SNPs within the gene.
Table 5 Genotype and allele frequencies of SNPs in HAO1 gene observed in 105 control subjects and 101 patients
SNP ID Genotype Genotype frequency (%) OR (95% CI) P-value* Allele Allele frequency (%) OR (95% CI) P-value*
Control Patient Control Patient
rs6055363 A/A 44.8 32 1.00 0.06 A 67.6 57 1.00 0.0265
A/G, G/G 55.2 68 1.72 (0.97-3.04) G 32.4 43 1.57 (1.05-2.36)
rs2294305 A/A 43.8 31 1.00 0.058 A 66.7 56.5 1.00 0.0343
A/G, G/G 56.2 69 1.74 (0.98-3.08) G 33.3 43.5 1.54 (1.03-2.30)
rs2235250 G/G 44.8 31.7 1.00 0.053 G 68.1 55.9 1.00 0.0110
G/A, A/A 55.2 68.3 1.75 (0.99-3.09) A 31.9 44.1 1.68 (1.12-2.51)
rs6077285 C/C 28 46.9 1.00 0.0057 C 57.5 66.8 1.00 0.0555
C/G, G/G 72 53.1 0.44 0(0.24-0.79) G 42.5 33.2 0.67 (0.45-1.01)
rs2294301 C/C 34.3 53.5 1.00 0.0054 C 60 69.8 1.00 0.0373
C/G, G/G 65.7 46.5 0.45 0(0.26-0.80) G 40 30.2 0.65 (0.43-0.98)
rs2423326 G/G 34.3 54.5 1.00 0.0035 G 60 72.8 1.00 0.0061
G/A, A/A 65.7 45.5 0.44 0(0.25-0.77) A 40 27.2 0.56 (0.37-0.85)
rs6118004 T/T 33.3 58 1.00 0.0004 T 60 74.5 1.00 0.0018
T/C, C/C 66.7 42 0.36 0(0.21-0.64) C 40 25.5 0.51 (0.34-0.78)
rs2205818 A/A 35.2 57.4 1.00 0.0013 A 61.9 74.3 1.00 0.0072
A/G, G/G 64.8 42.6 0.40 (0.23-0.71) G 38.1 25.7 0.56 (0.37-0.86)
rs2142697 T/T 34 56.6 1.00 0.0012 T 61.2 74.2 1.00 0.0050
T/C, C/C 66 43.4 0.40 (0.22-0.70) C 38.8 25.8 0.55 (0.36-0.83)
rs6140463 G/G 35.2 58 1.00 0.001 G 61.4 74.5 1.00 0.0046
G/A, A/A 64.8 42 0.39 (0.22-0.69) A 38.6 25.5 0.54 (0.36-0.83)
rs2235245 C/C 35.2 58.4 1.00 0.0008 C 61.4 75.2 1.00 0.0026
C/G, G/G 64.8 41.6 0.39 (0.22-0.68) G 38.6 24.8 0.52 (0.34-0.80)
rs6086287 A/A 72.4 58.4 1.00 0.035 A 84.8 77.2 1.00 0.0510
A/C, C/C 27.6 41.6 1.87 (1.04-3.34) C 15.2 22.8 1.64 (0.99-2.70)
rs2255183 T/T 71.4 56.4 1.00 0.025 T 84.3 76.2 1.00 0.0399
T/C, C/C 28.6 43.6 1.93 (1.08-3.44) C 15.7 23.8 1.67 (1.02-2.74)
OR, odds ratio; CI, confidence interval.
*Uncorrected P-value.
Significant P-values are indicated in bold.
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carboxyglutamate (gla) protein. This vitamin K-dependent
protein is related to bone resorption and may change
blood levels of calcium ions [25]. In mouse, osteocalcin
has a similar pattern of expression and identical structural
features to nephrocalcin, a calcium-binding protein par-
tially purified from kidney that plays a role in calcium re-
absorption and in prevention of nephrolithiasis [26].
Therefore, osteocalcin might associate with kidney stone
disease. However, the Hind III polymorphism located at
the promoter region was not correlated with calcium oxal-
ate stone disease in Taiwanese patients [27]. In the present
study, rs759330 located 144 bp downstream of BGLAP
gene showed significant differences of allele frequency be-
tween the 216 patients and 216 control subjects with P =
0.0001. This result indicates the association of BGLAP
and the disease; however, the functional SNP could not beidentified. Only one exonic SNP, rs182775321, was de-
tected in BGLAP by DNA sequencing but it showed no
significant differences of genotype and allele frequencies
between the patient and control groups. Interestingly,
while we were looking for other candidate genes close to
rs759330 that may be involved in the disease, we found
that this SNP is located in the 3′UTR of PAQR6 gene en-
coding progestin and adipoQ receptor family member VI.
Prediction for miRNA binding site by using MicroCosm
Targets at EMBL-EBI (http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5/) revealed that rs759330 is
located at the binding site of hsa-miR-424*. The entire se-
quence of predicted binding site for hsa-miR-424* at 3′
UTR of PAQR6 gene including the position of rs759330 is
shown (Additional file 8: Figure S4).
PAQR6 has been reported to have progestin-binding
characteristics [28]. The kidney was found to be the site
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stimulate Ca2+ reabsorption at distal part of the nephron
[30]. The level of PAQR6 expression may correlate with
progesterone that stimulates Ca2+ reabsorption in the
kidney and it may be involved in pathogenesis of KSD.
In the present study, we found that the patient group
had significantly higher proportions of C allele of
rs759330 than the control group, indicating that C allele
was susceptible to KSD. Since rs759330 is located at
binding site of hsa-miR-424*, the presence of rs759330-
C allele may decrease PAQR6 expression leading to re-
duction of progesterone receptors in the kidney. The re-
duction of progesterone molecule which associates with
decreased level of Ca2+ reabsorption may increase risk of
KSD. For this reason, rs759330 may affect miRNA bind-
ing resulting in mRNA expression level. The relationship
between PAQR6 and KSD requires further investigation.
AHSG gene encodes fetuin-A or alpha-2-HS-glycopro-
tein, a circulating calcium-regulatory glycoprotein that
inhibits extraosseous calcification. It has been reported
that the patients with urolithiasis had lower urinary
fetuin-A levels compared with that of healthy subjects
[31]. In addition, two AHSG gene polymorphisms,
rs4917 and rs4918, were evaluated in 103 Turkish pa-
tients with calcium oxalate nephrolithiasis and 73
healthy subjects. The results revealed that rs4918 was
associated with higher risk for renal calcium oxalate
stone formation [32]. In our study, 3 SNPs on micro-
array were initially analyzed and the allele and genotype
frequencies of rs2070634 and rs2070635 were signifi-
cantly different between the patient and control groups
(Table 3). Two AHSG haplotypes were slightly associated
with kidney stone risk, haplotype AGC with decreased
disease risk and haplotype ATT with increased disease
risk. However, the associations of both haplotypes were
not statistically significant after correction. Two non-
synonymous SNPs, rs4917 and rs4918, were also geno-
typed in 112 each of patient and control groups but no
significant differences of allele and genotype frequencies
between the patient and control groups were observed.
This result is different from that of the previous study,
showing that rs4918 was associated with KSD in Turkish
patients [31]. Our result demonstrated that rs4918 was
not associated with kidney stone formation in the popu-
lation studied (P = 0.66, OR 0.78, 95% CI 0.51-1.18). The
different result may be attributable to genetic diversity
among these two populations and also the small num-
bers of patients and control subjects included in the
present study.
CD44 gene encodes CD44 molecule. This transmem-
brane protein is a receptor for hyaluronic acid (HA) and
can also interact with osteopontin (OPN), a major com-
ponent in the urinary stone matrix that inhibits nucle-
ation, growth, and aggregation of CaOx crystals and alsoreduces binding of crystals to renal epithelial cells in
vitro [33-36]. In a study in rat, the expression of HA,
OPN, and CD44 by injured/regenerating tubular cells
seems to play a role in crystal retention in the kidney
[37]. Thus, CD44 may be a candidate gene of KSD. In
this association study, genotype or allele frequencies of
13 SNPs in the CD44 gene were significantly different
between the patient and control groups (Table 4). Hap-
lotypes associated with decreased and increased kidney
stone risk were also identified but they were observed in
a different haplotype block with different frequency
(Additional file 5: Table S3). This study indicates the po-
tency of CD44 gene for KSD in the population studied.
However, the variants causing the disease should be fur-
ther investigated.
HAO1 gene encodes glycolate oxidase 1. Human glyco-
late oxidase catalyzes flavin mononucleotide -dependent
oxidation of glycolate to glyoxylate, and of glyoxylate to
oxalate. The presence of glycolate oxidase 1 in liver and
kidney peroxisomes and its ability to oxidize glyoxylate to
oxalate, a key metabolite in the kidney stone formation, is
of particular importance for individuals with primary
hyperoxaluria type I, as a consequence of their inability to
convert glyoxylate to glycine in the peroxisome [38-40]. In
our study, we found 13 different SNPs, having either
genotype or allele frequencies with significant differences
between the patient and control groups (Table 5). Haplo-
types associated with decreased and increased disease
risks were also observed (Additional file 7: Table S4), indi-
cating the potency of HAO1 gene for KSD in the popula-
tion studied although the variants associated with the
disease should be further investigated.
Although a genome-wide association study (GWAS)
was conducted in 101 patients and 105 control subjects in
the beginning of this study, a potential variation could not
be identified. Initially, 57 SNPs distributed on the genome
were found to have statistical significance after correction
by qualified 684,142 SNPs on microarray. Of these, 28
SNPs were located in the gene regions but the ratios of
significant SNPs over non-significant SNPs within the
same genes were low. In addition, only 6 SNPs were pre-
dicted to have functional impacts as examined by SNP
Function Prediction (FuncPred, The National Institute of
Environmental Health Sciences (NIEHS) http://snpinfo.
niehs.nih.gov/snpinfo/snpfunc.htm) and when one SNP
each in a gene of interest was selected to for validation, it
was found to be false positive results. The unsuccessful
analysis by GWAS in this study may be attributable to the
small sample size leading to low statistical power (power
0.44 as calculated by Quanto, http://biostats.usc.edu/
software). This led us to change the analysis method to be
candidate gene association study. When an alternative ap-
proach by candidate gene association study of 104 re-
ported candidate genes were taken, a number of potential
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was validated in 216 each of patient and control groups
by HRM method, the statistical power was increased to
be 0.87. However, a larger sample size is required to val-
idate the relationship of other candidate genes. Al-
though a low-powered sample size is a limitation of this
study, the association study based on the reported can-
didate genes has made it possible to identify the poten-
tial candidate genes and the associated SNPs for KSD in
the studied population.
Conclusions
In conclusion, our study suggests that BGLAP together
with PAQR6, AHSG, HAO1, and CD44 are potential
candidates associated with KSD in NE Thai patients.
Replication studies with a larger sample size are neces-
sary to validate these associations. Of these, PAQR6
comes into our view as the most potent candidate since
the associated SNP rs759330 is located in the miRNA
binding, which may affect mRNA expression level.
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